Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in Patients Receiving Neoadjuvant Chemotherapy for Hormone Receptor-Positive HER2-Negative Breast Cancer.

• Tác giả: Fernando Nalesso Aguiar, Edmund Chada Baracat, José Roberto Filassi, Juliana Pierobon Gomes da Cunha, Rodrigo Gonçalves, Fernando Wladimir Silva Rivas, Thais Perez Vazquez
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc , 2025
• Bộ sưu tập: NCBI
• ID: 737859

Tóm tắt

 Breast cancer (BC) presents significant molecular heterogeneity, complicating prognosis and treatment strategies. Although molecular testing enhances our understanding of BC, high costs can limit accessibility in certain health care settings. This retrospective cohort study evaluates the prognostic value of Magee equation 3 (ME3) and residual cancer burden (RCB) in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative BC treated at the Instituto do Câncer do Estado de São Paulo from January 2011 to January 2024. We included 203 women, with a mean age of 50.2 years, diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative BC (stages I-III), who completed neoadjuvant chemotherapy followed by surgery. ME3 scores were categorized as low (<
 18), intermediate (18-25), and high (>
 25), whereas RCB was classified into 4 groups (0, 1, 2, or 3). Associations between ME3 and RCB categories were analyzed using χ